87 results on '"Kraft, Colleen S."'
Search Results
2. Determining qualitative effect size ratings using a likelihood ratio scatter matrix in diagnostic test accuracy systematic reviews.
- Author
-
Rubinstein, Matthew L., Kraft, Colleen S., and Parrott, J. Scott
- Subjects
- *
S-matrix theory , *META-analysis , *DIAGNOSIS methods , *CLOSTRIDIOIDES difficile , *TEST validity - Abstract
Background: Diagnostic test accuracy (DTA) systematic reviews (SRs) characterize a test's potential for diagnostic quality and safety. However, interpreting DTA measures in the context of SRs is challenging. Further, some evidence grading methods (e.g. Centers for Disease Control and Prevention, Division of Laboratory Systems Laboratory Medicine Best Practices method) require determination of qualitative effect size ratings as a contributor to practice recommendations. This paper describes a recently developed effect size rating approach for assessing a DTA evidence base. Methods: A likelihood ratio scatter matrix will plot positive and negative likelihood ratio pairings for DTA studies. Pairings are graphed as single point estimates with confidence intervals, positioned in one of four quadrants derived from established thresholds for test clinical validity. These quadrants support defensible judgments on "substantial", "moderate", or "minimal" effect size ratings for each plotted study. The approach is flexible in relation to a priori determinations of the relative clinical importance of false positive and false negative test results. Results and conclusions: This qualitative effect size rating approach was operationalized in a recent SR that assessed effectiveness of test practices for the diagnosis of Clostridium difficile. Relevance of this approach to other methods of grading evidence, and efforts to measure diagnostic quality and safety are described. Limitations of the approach arise from understanding that a diagnostic test is not an isolated element in the diagnostic process, but provides information in clinical context towards diagnostic quality and safety. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period.
- Author
-
Aldrete, Sol del Mar, Kraft, Colleen S., Magee, Matthew J., Chan, Austin, Hutcherson, Don, Langston, Amelia A., Greenwell, Brian I., Burd, Eileen M., and Friedman‐Moraco, Rachel
- Subjects
- *
CLOSTRIDIOIDES difficile , *HEMATOPOIETIC stem cell transplantation , *COMPLICATIONS from organ transplantation , *CANCER chemotherapy , *PREVENTIVE medicine , *DISEASE risk factors - Abstract
Background Hematopoietic stem cell transplant ( HSCT) recipients represent a high-risk group for developing Clostridium difficile ( CD) infection ( CDI). We aimed to identify specific risk factors for CDI in an HSCT patient population during the peritransplant period. Methods We performed a case-control study within a cohort of HSCT patients who received a transplant from November 2010 to March 2013. Cases had a clinical presentation compatible with CDI and a positive stool sample Xpert® C. difficile test. Controls were CDI negative and matched on age, gender, and transplant type. Peritransplant period was defined as −30 days or time of stem cell mobilization maneuver to 30 days post transplant in autologous SCT or 90 days post transplant in allogeneic SCT. Results Of 781 HSCTs performed during the study period, 650 (83.2%) had a stool sample submitted for CD testing. Eight-six (13.2%) cases with CDI were identified. Most of the cases were diagnosed within a week after transplantation (median of 5 days). In adjusted analysis, prior hospitalization (odds ratio [ OR]: 2.01, 95% confidence interval [ CI] 1.2-3.36), prior cephalosporin administration ( OR 2.72, 95% CI: 1.54-4.83), and prior chemotherapy ( OR: 3.26, 95% CI: 1.92-5.5) were significantly associated with CDI. Conclusions Hospitalization, and prior antibiotic and chemotherapy use are risk factors that are not easily modifiable, which emphasizes the need to start investigating preventive or prophylactic strategies in this high-risk population. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Viral Hemorrhagic Fever Diagnostics.
- Author
-
Racsa, Lori D., Kraft, Colleen S., Olinger, Gene G., and Hensley, Lisa E.
- Subjects
- *
HEMORRHAGIC fever , *FILOVIRIDAE , *PUBLIC health , *EPIDEMIC research , *DIAGNOSIS - Abstract
There are 4 families of viruses that cause viral hemorrhagic fever (VHF), including Filoviridae. Ebola virus is one virus within the family Filoviridae and the cause of the current outbreak of VHF inWest Africa. VHF-endemic areas are found throughout the world, yet traditional diagnosis of VHF has been performed in large reference laboratories centered in Europe and the United States. The large amount of capital needed, as well as highly trained and skilled personnel, has limited the availability of diagnostics in endemic areas except in conjunction with governmental and nongovernmental entities. However, rapid diagnosis of VHF is essential to efforts that will limit outbreaks. In addition, increased global travel suggests VHF diagnoses may be made outside of the endemic areas. Thus, understanding how to diagnose VHF is imperative for laboratories worldwide. This article reviews traditional and current diagnostic modalities for VHF. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States.
- Author
-
Kraft, Colleen S., Hewlett, Angela L., Koepsell, Scott, Winkler, Anne M., Kratochvil, Christopher J., Larson, LuAnn, Varkey, Jay B., Mehta, Aneesh K., Lyon III, G. Marshall, Friedman-Moraco, Rachel J., Marconi, Vincent C., Hill, Charles E., Sullivan, James N., Johnson, Daniel W., Lisco, Steven J., Mulligan, Mark J., Uyeki, Timothy M., McElroy, Anita K., Sealy, Tara, and Campbell, Shelley
- Subjects
- *
EPIDEMICS , *KIDNEY transplantation , *ARTIFICIAL respiration , *MULTIPLE organ failure , *PUBLIC health , *CONVALESCENT plasma ,TREATMENT of Ebola virus diseases - Abstract
Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management. Methods. We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM- 100802) and convalescent plasma. Results. While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date. Conclusions. It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Fecal Microbiota Transplantation: Tales of Caution.
- Author
-
Khanna, Sahil and Kraft, Colleen S
- Subjects
- *
TREATMENT of escherichia coli diseases , *MEDICAL screening , *CLOSTRIDIOIDES difficile , *FECAL microbiota transplantation , *BACTERIAL toxins - Abstract
The article focuses on Fecal Microbiota Transplantation. Topics discussed include Microbiota-based therapies are generally considered safe and are the cornerstone of management of patients with recurrent Clostridioides difficile infection, with high success rates to prevent future recurrences; and Health screening for stool donors who participate in studies and clinical practice of microbiome-based therapies have evolved.
- Published
- 2021
- Full Text
- View/download PDF
7. The Value of Case-Based Teaching Vignettes in Clinical Microbiology Rounds.
- Author
-
Spicer, Jennifer O., Kraft, Colleen S., Burd, Eileen M., Armstrong, Wendy S., and Guarner, Jeannette
- Subjects
- *
MICROBIOLOGY education , *VIGNETTES (Teaching technique) , *CURRICULUM research , *CASE method (Teaching) , *TEACHING methods - Abstract
Objectives: To describe the implementation and evaluation of a case-based microbiology curriculum during daily microbiology rounds. Methods: Vignettes consist of short cases with images and questions that facilitate discussion among microbiologists, pathologists, infectious disease physicians, and trainees (residents and fellows). We performed a survey to assess the value of these vignettes to trainees. Results: Motivation to come to rounds on time increased from 60% to 100%. Trainees attending rounds after implementation of the vignettes perceived the value of microbiology rounds to be significantly higher compared with those who attended rounds before implementation (P = .04). Pathology residents found that vignettes were helpful for retaining knowledge (8.3 of 10 points). Conclusions: The vignettes have enhanced the value of microbiology rounds by serving as a formalized curriculum exposing trainees from multiple specialties to various microbiology topics. Emphasis on interdisciplinary interactions between clinical and laboratory personnel was highlighted with this case-based curriculum. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Interpreting Laboratory Results in Transgender Patients on Hormone Therapy.
- Author
-
Roberts, Tiffany K., Kraft, Colleen S., French, Deborah, Ji, Wuyang, Wu, Alan H.B., Tangpricha, Vin, and Fantz, Corinne R.
- Subjects
- *
HORMONE therapy , *TRANSGENDER people , *HEMOGLOBINS , *HEMATOCRIT , *LOW density lipoproteins , *ALKALINE phosphatase - Abstract
Abstract: Background: Clinical guidelines recommend laboratory monitoring of transgender persons on cross-sex hormone therapy, but gender-specific reference intervals leave clinicians with the dilemma of deciding what is “normal” for each patient. The goal of this study was to identify consistent changes in measurands with hormone therapy and determine which reference interval is appropriate. Methods: Laboratory data were abstracted from the medical records of 55 male-to-female patients on hormone therapy and compared with 20 male and 20 female nontransgender subjects. Results: Hemoglobin, hematocrit, and low-density lipoprotein resembled female values (P < .005), while alkaline phosphatase, potassium, and creatinine resembled male values (P < .05). Triglycerides were higher (P < .005) than either the male or female groups. The remainder of the measurands showed no differences. Conclusions: Use of correct reference intervals in interpreting laboratory results reduces the risk of testing-related diagnostic error. Preliminary data suggest that new reference intervals need to be established for transgender patients. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
9. Interpreting Quantitative Cytomegalovirus DNA Testing: Understanding the Laboratory Perspective.
- Author
-
Kraft, Colleen S., Armstrong, Wendy S., and Caliendo, Angela M.
- Subjects
- *
QUANTITATIVE research , *CYTOMEGALOVIRUSES , *DNA , *MICROBIOLOGICAL assay , *PATHOLOGICAL laboratories , *BLOOD plasma , *VIRAL load - Abstract
Cytomegalovirus (CMV) is an important cause of morbidity and mortality in transplant patients, and is typically monitored using laboratory-developed quantitative molecular assays. Clinicians who use quantitative CMV DNA testing should be aware of a number of aspects of testing that will aid in decision making while managing CMV disease in their patients. These include (1) the specimen type used (whole blood or plasma), (2) the limit of detection and limit of quantification chosen by the clinical laboratory, (3) the linear range of the assay, (4) the reproducibility of the assay within the institution, and (5) the wide variability of viral load values among different assays. The biologic properties of CMV, including its variability within the host and of its half-life, are also important factors in the clinical testing for this virus. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection.
- Author
-
Basu, Debby, Kraft, Colleen S., Murphy, Megan K., Campbell, Patricia J., Tianwei Yu, Hraber, Peter T., Irene, Carmela, Pinter, Abraham, Chomba, Chomba, Mulenga, Joseph, Kilembe, William, Allen, Susan A., Derdeyn, Cynthia A., and Hunter, Eric
- Subjects
- *
HIV infections , *SEXUALLY transmitted diseases , *HIV , *HIV-positive persons , *LENTIVIRUS diseases - Abstract
Background: The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. Results: Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. Conclusions: These data suggest that the lack of development of IgG antibodies, as reflected in autologous Nabs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. A 68-Year-Old Musician With Cough, Wheezing, and a Lung Mass.
- Author
-
Alikhan, Mir M, Kraft, Colleen S, Shih, Jennifer A, Lee, F Eun-Hyung, Auffermann, William F, and Berkowitz, David M
- Abstract
A 68-year-old man was referred to the pulmonary clinic for evaluation of cough and a 5-cm right upper lobe mass. He was in his usual state of health until 1 year prior when he developed intermittent cough, wheezing, and sinus congestion. He denied any sputum production or hemoptysis. He also denied any fevers, chills, or weight loss. He had received various treatments within the prior 6 months, including short courses of oral prednisone, levofloxacin, and bronchodilators, without any relief of his symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Successful use of Plasma Preparation Tubes™ (PPTs) in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test
- Author
-
Kraft, Colleen S., Binongo, José Nilo G., Burd, Eileen M., Eaton, Molly E., McCloskey, Cindy B., Fernandes, Helen, Hill, Charles E., and Caliendo, Angela M.
- Subjects
- *
DIAGNOSIS of HIV infections , *BLOOD plasma , *VIRAL load , *STATISTICAL correlation , *DNA viruses , *ETHYLENEDIAMINETETRAACETIC acid - Abstract
Abstract: Background: Since switching to the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v. 1.0 from the Amplicor HIV-1 Monitor Test, v. 1.5, an increase in detectable viral load results was noted. We were concerned that this was due to the use of Plasma Preparation Tubes (PPT) in this test. Objective: To assess the impact of different pre-analytical processing conditions on HIV-1 viral load results on the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test. Study design: Sixty-three HIV-infected patients were consented and had 3 PPTs and 1 K2EDTA drawn for HIV-1 viral load testing. Three methods of PPT processing were compared against the referent K2EDTA tube which was spun at 1100× g for 20min, poured off and frozen; PPT1 was refrigerated with an additional centrifugation prior to testing, PPT2 was processed similarly to EDTA, and PPT3 was centrifuged, frozen and centrifuged again prior to testing. Results: PPT1 and PPT3 yielded results that were most similar to the referent EDTA processing, with a concordance correlation coefficient (CCC) of 0.80 and 0.85, compared to PPT2 with CCC of 0.37. Both PPT1 and PPT3 involved additional centrifugation prior to testing. In 26 patients with residual samples from the PPT2 processing, 9 (34.6%) were found to have the presence of proviral DNA, which likely contributed to the elevated HIV-1 RNA viral loads in these individuals. Conclusion: PPTs can be used in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test with an additional centrifugation in order to avoid misleading elevated HIV-1 RNA viral loads that may change patient management. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
13. Cytomegalovirus DNA stability in EDTA anti-coagulated whole blood and plasma samples
- Author
-
Abdul-Ali, Deborah, Kraft, Colleen S., Ingersoll, Jessica, Frempong, Mona, and Caliendo, Angela M.
- Subjects
- *
CYTOMEGALOVIRUSES , *DNA , *STABILITY (Mechanics) , *VIRAL load , *IMMUNOSUPPRESSION , *ANTICOAGULANTS , *BLOOD testing , *BLOOD plasma , *ETHYLENEDIAMINETETRAACETIC acid - Abstract
Abstract: Background: Cytomegalovirus (CMV) DNA viral load testing is routinely performed in centers that serve patients that are immunosuppressed from organ or hematopoietic stem cell transplantation. Clinical laboratories that offer this testing often face practical concerns about the storage of these specimens to ensure accurate measurement for patient care. The published studies that assess CMV DNA stability at 4°C have done so only up to 72h. Objective: Our objective was to determine the stability of CMV DNA in whole blood and plasma for clinical viral load testing over a 14day period. Study design: Twenty-one plasma samples that were CMV-positive and twenty whole blood samples (including eleven CMV-negative whole blood samples spiked with CMV-positive plasma) were stored at 4°C and underwent extraction and amplification at 3 time points: Day 0, Day 7, and Day 14. Results: Log10 values were calculated and t-test was performed on the values comparing Day 0 to Day 14 for plasma and whole blood. There was no statistically significant difference between Day 0 and Day 14 for both specimen types, including the CMV-negative whole blood specimens that were spiked with CMV-positive plasma. Conclusions: CMV DNA in plasma and whole blood is stable for 14days at a temperature of 4°C. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
14. Clinical Laboratory Values in Human Ebola Virus Disease Support the Relevance of the Intramuscular Ebola-Kikwit Rhesus Model.
- Author
-
Reisler, Ronald B, Kraft, Colleen S, Bavari, Sina, and Cardile, Anthony P
- Subjects
- *
BIOMARKERS , *BIOLOGICAL models , *EBOLA virus disease , *PRIMATES , *VIREMIA , *EBOLA virus - Published
- 2018
- Full Text
- View/download PDF
15. The Burden and Impact of Early Post-transplant Multidrug-Resistant Organism Detection Among Renal Transplant Recipients, 2005–2021.
- Author
-
Babiker, Ahmed, Karadkhele, Geeta, Bombin, Andrei, Watkins, Rockford, Robichaux, Chad, Smith, Gillian, Beechar, Vivek B, Steed, Danielle B, Jacobs, Jesse T, Read, Timothy D, Satola, Sarah, Larsen, Christian P, Kraft, Colleen S, Pouch, Stephanie M, and Woodworth, Michael H
- Abstract
Background Reducing the burden of multidrug-resistant organism (MDRO) colonization and infection among renal transplant recipients (RTRs) may improve patient outcomes. We aimed to assess whether the detection of an MDRO or a comparable antibiotic-susceptible organism (CSO) during the early post-transplant (EPT) period was associated with graft loss and mortality among RTRs. Methods We conducted a retrospective cohort study of RTRs transplanted between 2005 and 2021. EPT positivity was defined as a positive bacterial culture within 30 days of transplant. The incidence and prevalence of EPT MDRO detection were calculated. The primary outcome was a composite of 1-year allograft loss or mortality following transplant. Multivariable Cox hazard regression, competing risk, propensity score–weighted sensitivity, and subgroup analyses were performed. Results Among 3507 RTRs, the prevalence of EPT MDRO detection was 1.3% (95% CI, 0.91%–1.69%) with an incidence rate per 1000 EPT-days at risk of 0.42 (95% CI, 0.31–0.57). Among RTRs who met survival analysis inclusion criteria (n = 3432), 91% (3138/3432) had no positive EPT cultures and were designated as negative controls, 8% (263/3432) had a CSO detected, and 1% (31/3432) had an MDRO detected in the EPT period. EPT MDRO detection was associated with the composite outcome (adjusted hazard ratio [aHR], 3.29; 95% CI, 1.21–8.92) and death-censored allograft loss (cause-specific aHR, 7.15; 95% CI, 0.92–55.5; subdistribution aHR, 7.15; 95% CI, 0.95–53.7). A similar trend was seen in the subgroup and sensitivity analyses. Conclusions MDRO detection during the EPT period was associated with allograft loss, suggesting the need for increased strategies to optimize prevention of MDRO colonization and infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Diagnostic and Therapeutic Considerations for Oncology Patients With Clostridium difficile Infection.
- Author
-
Woodworth, Michael H. and Kraft, Colleen S.
- Subjects
- *
CANCER patients , *CLOSTRIDIOIDES difficile , *CLOSTRIDIUM diseases , *DIARRHEA - Abstract
The article presents information on the diagnosis and treatment of oncology patients with Clostridium difficile infection. Topics include the article "Clostridium difficile-associated Diarrhea in the Oncology Patient" by K. Neemann and A. Freifeld published in the "Journal of Oncology Practice" in 2017, understanding C difficile infection, and the microbial treatment of the infection and dysbiosis.
- Published
- 2017
- Full Text
- View/download PDF
17. Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease.
- Author
-
Kraft, Colleen S.
- Subjects
- *
ANTIVIRAL agents , *RANDOMIZED controlled trials , *VIREMIA , *THERAPEUTICS ,TREATMENT of Ebola virus diseases - Abstract
The author discusses a research on considering favipiravir as a countermeasure in future randomized controlled trials against Ebola virus disease by Chang-Qing Bai and colleagues, published within the issue. Topics discussed include transfusion of convalescent whole blood from five male survivors to eight Ebola-infected females; outbreak of Ebola disease in the Lassa fever zone in Sierra Leone; and clinical trials in Sierra Leone supporting role of favipiravir in treatment of viremia.
- Published
- 2016
- Full Text
- View/download PDF
18. Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone.
- Author
-
Shantha, Jessica G., Crozier, Ian, Kraft, Colleen S., Grant, Donald G., Goba, Augustine, Hayek, Brent R., Hartley, Caleb, Barnes, Kayla G., Uyeki, Timothy M., Schieffelin, John, Garry, Robert F., Bausch, Daniel G., Farmer, Paul E., Mattia, John G., Vandy, Matthew J., and Yeh, Steven
- Subjects
- *
EBOLA virus , *EBOLA virus disease , *VISUAL acuity , *VISION disorders , *INFECTION prevention , *CATARACT surgery , *EYE care , *HIV prevention - Abstract
Background: Following the West African Ebola virus disease (EVD) outbreak of 2013–2016 and more recent EVD outbreaks in the Democratic Republic of Congo, thousands of EVD survivors are at-risk for sequelae including uveitis, which can lead to unremitting inflammation and vision loss from cataract. Because of the known risk of Ebola virus persistence in ocular fluid and the need to provide vision-restorative, safe cataract surgery, the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study was implemented in Sierra Leone. During implementation of this multi-national study, challenges included regulatory approvals, mobilization, community engagement, infection prevention and control, and collaboration between multiple disciplines. In this report, we address the multifacted approach to address these challenges and the impact of implementation science research to address an urgent clinical subspecialty need in an outbreak setting. Methodology/Principal findings: Given the patient care need to develop a protocol to evaluate ocular fluid for Ebola virus RNA persistence prior to cataract surgery, as well as protocols to provide reassurance to ophthalmologists caring for EVD survivors with cataracts, the EVICT study was designed and implemented through the work of the Ministry of Health, Sierra Leone National Eye Programme, and international partnerships. The EVICT study showed that all 50 patients who underwent ocular fluid sampling at 19 and 34 months, respectively, tested negative for Ebola virus RNA. Thirty-four patients underwent successful cataract surgery with visual acuity improvement. Here we describe the methodology for study implementation, challenges encountered, and key issues that impacted EVD vision care in the immediate aftermath of the EVD outbreak. Key aspects of the EVICT study included defining the pertinent questions and clinical need, partnership alignment with key stakeholders, community engagement with EVD survivor associations, in-country and international regulatory approvals, study site design for infection prevention and control, and thorough plans for EVD survivor follow-up care and monitoring. Challenges encountered included patient mobilization owing to transportation routes and distance of patients in rural districts. Strong in-country partnerships and multiple international organizations overcame these challenges so that lessons learned could be applied for future EVD outbreaks in West and Central Africa including EVD outbreaks that are ongoing in Guinea and Democratic Republic of Congo. Conclusions/Significance: The EVICT Study showed that cataract surgery with a protocol-driven approach was safe and vision-restorative for EVD survivors, which provided guidance for EVD ophthalmic surgical care. Ophthalmologic care remains a key aspect of the public health response for EVD outbreaks but requires a meticulous, yet partnered approach with international and local in-country partners. Future efforts may build on this framework for clinical care and to improve our understanding of ophthalmic sequelae, develop treatment paradigms for EVD survivors, and strengthen vision health systems in resource-limited settings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic.
- Author
-
Berenson, Charles S, Lashner, Bret, Korman, Louis Y, Hohmann, Elizabeth, Deshpande, Abhishek, Louie, Thomas J, Sims, Matthew, Pardi, Darrell, Kraft, Colleen S, Wang, Elaine E L, Cohen, Stuart H, Feuerstadt, Paul, Oneto, Caterina, Misra, Bharat, Pullman, John, De, Ananya, Memisoglu, Asli, Lombardi, David A, Hasson, Brooke R, and McGovern, Barbara H
- Subjects
- *
CLOSTRIDIUM disease treatment , *THERAPEUTICS , *STATISTICS , *RELATIVE medical risk , *GUT microbiome , *CLOSTRIDIUM diseases , *DISEASE relapse , *RISK assessment , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *COMPARATIVE studies , *DISEASE prevalence , *DATA analysis , *COMORBIDITY , *ANTIBIOTICS , *DISEASE risk factors , *EVALUATION , *ADULTS - Abstract
Background Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with medical conditions such as malignancy or immunosuppression. In a phase 3, double-blind, placebo-controlled, randomized trial (ECOSPOR III), fecal microbiota spores, live (VOWST, Seres Therapeutics; hereafter "VOS," formerly SER-109), an oral microbiota therapeutic, significantly reduced the risk of rCDI at week 8. We evaluated the efficacy of VOS compared with placebo in patients with comorbidities and other risk factors for rCDI. Methods Adults with rCDI were randomized to receive VOS or placebo (4 capsules daily for 3 days) following standard-of-care antibiotics. In this post hoc analysis, the rate of rCDI through week 8 was assessed in VOS-treated participants compared with placebo for subgroups including (i) Charlson comorbidity index (CCI) score category (0, 1–2, 3–4, ≥5); (ii) baseline creatinine clearance (<30, 30–50, >50 to 80, or >80 mL/minute); (iii) number of CDI episodes, inclusive of the qualifying episode (3 and ≥4); (iv) exposure to non-CDI-targeted antibiotics after dosing; and (v) acid-suppressing medication use at baseline. Results Of 281 participants screened, 182 were randomized (59.9% female; mean age, 65.5 years). Comorbidities were common with a mean overall baseline age-adjusted CCI score of 4.1 (4.1 in the VOS arm and 4.2 in the placebo arm). Across all subgroups analyzed, VOS-treated participants had a lower relative risk of recurrence compared with placebo. Conclusions In this post hoc analysis, VOS reduced the risk of rCDI compared with placebo, regardless of baseline characteristics, concomitant medications, or comorbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Fecal Microbiota Transplant for Refractory Clostridium difficile Infection Interrupts 25-Year History of Recurrent Urinary Tract Infections.
- Author
-
Wang, Tiffany, Kraft, Colleen S, Woodworth, Michael H, Dhere, Tanvi, and Eaton, Molly E
- Published
- 2018
- Full Text
- View/download PDF
21. Use of Standard Donors in Fecal Microbiotal Transplants.
- Author
-
Xiao Jing Wang, Kraft, Colleen S., and Dhere, Tanvi
- Subjects
- *
FECAL microbiota transplantation , *CLOSTRIDIOIDES difficile , *THERAPEUTICS - Abstract
A letter to the editor about the use fecal microbiota transplantation (FMT) in the treatment of Clostridium difficile infection (CDI) is presented.
- Published
- 2015
- Full Text
- View/download PDF
22. Diverticulitis after Fecal Microbiota Transplant for C. difficile Infection.
- Author
-
Mandalia, Amar, Kraft, Colleen S, and Dhere, Tanvi
- Subjects
- *
DIVERTICULITIS , *FECAL microbiota transplantation , *CLOSTRIDIOIDES difficile , *DIAGNOSIS , *THERAPEUTICS - Abstract
The article presents a case study of diverticulitis after fecal microbiota transplant (FMT) for the treatment of recurrent clostridium difficile infection (CDI) in a 78-year old Caucasian woman.
- Published
- 2014
- Full Text
- View/download PDF
23. Approach to Cataract Surgery in an Ebola Virus Disease Survivor with Prior Ocular Viral Persistence.
- Author
-
Wells, Jill R, Crozier, Ian, Kraft, Colleen S, Sexton, Mary Elizabeth, Hill, Charles E, Ribner, Bruce S, Bavari, Sina, Palacios, Gustavo, Pearce, William A, Van Gelder, Russell, Grossniklaus, Hans, Cazares, Lisa, Zeng, Xiankung, Shantha, Jessica G, Yeh, Steven, and Zeng, Xiankun
- Subjects
- *
CATARACT , *RESEARCH , *EBOLA virus disease , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *EBOLA virus , *EYE , *COMPARATIVE studies - Abstract
A 46-year-old patient with previously documented Ebola virus persistence in his ocular fluid, associated with severe panuveitis, developed a visually significant cataract. A multidisciplinary approach was taken to prevent and control infection. Ebola virus persistence was assessed before and during the operation to provide safe, vision-restorative phacoemulsification surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Auto-FMT successful in patients undergoing stem cell transplantation.
- Author
-
Ghizzone, Marley and Kraft, Colleen S.
- Published
- 2018
25. Assessing Viral Transfer During Doffing of Ebola-Level Personal Protective Equipment in a Biocontainment Unit.
- Author
-
Casanova, Lisa M, Erukunuakpor, Kimberly, Kraft, Colleen S, Mumma, Joel M, Durso, Francis T, Ferguson, Ashley N, Gipson, Christina L, Walsh, Victoria L, Zimring, Craig, and DuBose, Jennifer
- Subjects
- *
PREVENTION of communicable diseases , *EBOLA virus disease , *GLOVES , *HAND washing , *INDUSTRIAL safety , *PROTECTIVE clothing , *MEDICAL personnel , *MICROBIAL contamination , *SKIN , *SURGICAL scrub , *VIRAL load , *MEDICAL equipment contamination - Abstract
Background. Personal protective equipment (PPE) protects healthcare workers (HCWs) caring for patients with Ebola virus disease (EVD), and PPE doffing is a critical point for preventing viral self-contamination. We assessed contamination of skin, gloves, and scrubs after doffing Ebola-level PPE contaminated with surrogate viruses: bacteriophages MS2 and Φ6. Methods. In a medical biocontainment unit, HCWs (n = 10) experienced in EVD care donned and doffed PPE following unit protocols that incorporate trained observer guidance and alcohol-based hand rub (ABHR). A mixture of Φ6 (enveloped), MS2 (nonenveloped), and fluorescent marker was applied to 4 PPE sites, approximating body fluid viral load (Φ6, 105; MS2, 106). They performed a patient care task, then doffed. Inner gloves, face, hands, and scrubs were sampled for virus, as were environmental sites with visible fluorescent marker. Results. Among 10 HCWs there was no Φ6 transfer to inner gloves, hands, or face; 1 participant had Φ6 on scrubs at low levels (1.4 X 10²). MS2 transfer (range, 10¹-106) was observed to scrubs (n = 2), hands (n = 1), and inner gloves (n = 7), where it was highest. Most (n = 8) had only 1 positive site. Environmental samples with visible fluorescent marker (n = 21) were negative. Conclusions. Among experienced HCWs, structured, observed doffing using ABHR protected against hand contamination with enveloped virus. Nonenveloped virus was infrequent on hands and scrubs but common on inner gloves, suggesting that inner gloves, but not necessarily ABHR, protect against hand contamination. Optimizing doffing protocols to protect against all types of viruses may require reinforcing careful handling of scrubs and good glove/hand hygiene with effective agents. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Understanding Experience of Patients With Highly Infectious Diseases During Extended Isolation: A Design Perspective.
- Author
-
Matić, Zorana, Sala, Maria F. Wong, Tonetto, Leandro Miletto, Campiglia, Gabrielle Conrad, Morgan, Jill, DuBose, Jennifer R., Zimring, Craig M., and Kraft, Colleen S.
- Subjects
- *
WELL-being , *COMMUNICABLE diseases , *HOSPITAL building design & construction , *ATTITUDES of medical personnel , *RESEARCH methodology , *CROSS infection , *INTERVIEWING , *PATIENTS' attitudes , *EBOLA virus , *QUALITATIVE research , *AUTONOMY (Psychology) , *LONELINESS , *ISOLATION (Hospital care) , *THEMATIC analysis , *MEDICAL needs assessment , *HEALTH self-care - Abstract
Objectives: This study aimed to develop a better understanding of the unique needs of patients with highly infectious diseases and their perceptions of being placed in isolation. We explore the subjective experiences of patients treated for Ebola in a biocontainment unit (BCU) and the healthcare personnel who cared for them. Background: The 2014 Ebola outbreak and the COVID-19 pandemic have brought to focus some major challenges of caring for patients with serious infectious diseases. Previous studies on BCU design have looked at ways to prevent self- and cross-contamination, but very few have examined how the built environment can support an improved patient experience. Method: A qualitative study was conducted with four patients treated for Ebola and two critical care nurses who provided direct care to them at a single BCU in the U.S. Data were collected through in-depth semi-structured interviews to capture the actual patients' perception and experience of isolation. The interviews were analyzed using the thematic analysis approach. Results: The Ebola patients placed in source isolation perceived the BCU as an artificial environment where they lacked control, agency, autonomy, and independence. The physical separation from other patients, visitor restrictions, and staff wearing PPE contributed to feelings of social and emotional isolation, and loneliness. Conclusions: The isolation can take a toll on physiological and psychological well-being. A thoughtful design of isolation units may improve patients' experience by supporting human and social interactions, empowering patients through space flexibility and personalization of space, and supporting a more holistic approach to isolation care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Need for Clinicopathologic Correlation of Clostridium difficile Colitis in View of Molecular Diagnosis.
- Author
-
Guarner, Jeannette and Kraft, Colleen S.
- Subjects
- *
LETTERS to the editor , *CLOSTRIDIOIDES difficile - Abstract
A letter to the editor is presented in response to the article ''Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection" by A. Kufelnicka A and T. Kirn in the 2011 issue.
- Published
- 2012
- Full Text
- View/download PDF
28. Cytopathology of Vitreous Specimens in Acute Retinal Necrosis.
- Author
-
Hojjatie, Sara L., Shantha, Jessica G., O'Keefe, Ghazala D., Kraft, Colleen S., Voloschin, Alfredo, Grossniklaus, Hans, and Yeh, Steven
- Subjects
- *
CELLULAR pathology , *PARS plana , *AQUEOUS humor , *INTRAVITREAL injections , *CELL populations - Abstract
To report the cytopathology of vitreous biopsy samples in patients with acute retinal necrosis (ARN) who underwent pars plana vitrectomy (PPV). We also describe two patients with unique clinical courses, cytopathologic findings, and immune response A retrospective review of patients with ARN who developed retinal detachment (RD) and underwent PPV from 22011 to 2019 at the Emory Eye Center was performed to assess cytopathology findings of vitreous biopsy samples. Patient demographics and laboratory testing including aqueous humor PCR for viral pathogens were recorded. Additional clinical details abstracted included intravitreal injections, surgical procedures, and vitreous cytopathological reports including immunohistochemistry findings. Fourteen eyes of 12 patients with RD were reviewed. Ten eyes showed HSV DNA (71%) and 4 demonstrated VZV DNA (29%). All eyes received intravitreal antivirals (i.e. ganciclovir or foscarnet) with a median of 8.5 intravitreal injections per eye. Diagnoses prompting PPV included tractional RD in 14 eyes (100%), rhegmatogenous RD in 8 eyes (57%), vitreous hemorrhage in 4 eyes (29%) and vitreous opacity in 4 (29%). Ophthalmic pathology reports showed lymphocyte populations in 10 eyes (71%) with a CD3 + T-cell predominance in two patients where immunohistochemistry of CD3+ and CD20+ for T- and B-cell populations was performed. Observed immune cell populations included macrophages or histiocytes (11 eyes, 79%) and polymorphonuclear cells in 4 eyes (29%). Initial median VA was 2.5 (IQR 2.0–3.0) and improved to 2.0 (IQR 1.48–3.00, p =.48) at 6-months and 1.8 (IQR 1.2–3.0, p =.45) at 12 months follow-up. Our cohort of ARN patients undergoing PPV show a spectrum of immunologic findings with the majority demonstrating a lymphocytic response. Histiocytes, macrophages, and PMNs were also observed. Cytopathologic and immunologic studies suggest that both innate and adaptive immunity are responsible for the clinical disease findings observed in ARN. The variability of the response to treatment in patients with ARN may reflect patient-to-patient differences in their antigen-specific immune response. Understanding the immunologic response associated with ARN may provide valuable information regarding the dosing and timing of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Concordance of SARS-CoV-2 Results in Self-collected Nasal Swabs vs Swabs Collected by Health Care Workers in Children and Adolescents.
- Author
-
Waggoner, Jesse J., Vos, Miriam B., Tyburski, Erika A., Nguyen, Phuong-Vi, Ingersoll, Jessica M., Miller, Candace, Sullivan, Julie, Griffiths, Mark, Stone, Cheryl, Benoit, Macarthur, Benedit, Laura, Seitter, Brooke, Jerris, Robert, Levy, Joshua M., Kraft, Colleen S., Farmer, Sarah, Peagler, Amanda, Wood, Anna, Westbrook, Adrianna L., and Morris, Claudia R.
- Abstract
Importance: Despite the expansion of SARS-CoV-2 testing, available tests have not received Emergency Use Authorization for performance with self-collected anterior nares (nasal) swabs from children younger than 14 years because the effect of pediatric self-swabbing on SARS-CoV-2 test sensitivity is unknown.Objective: To characterize the ability of school-aged children to self-collect nasal swabs for SARS-CoV-2 testing compared with collection by health care workers.Design, Setting, and Participants: Cross-sectional study of 197 symptomatic children and adolescents aged 4 to 14 years old. Individuals were recruited based on results of testing in the Children's Healthcare of Atlanta system from July to August 2021.Exposures: Children and adolescents were given instructional material consisting of a short instructional video and a handout with written and visual steps for self-swab collection. Participants first provided a self-collected nasal swab. Health care workers then collected a second specimen.Main Outcomes and Measures: The primary outcome was SARS-CoV-2 detection and relative quantitation by cycle threshold (Ct) in self- vs health care worker-collected nasal swabs when tested with a real-time reverse transcriptase-polymerase chain reaction test with Emergency Use Authorization.Results: Among the study participants, 108 of 194 (55.7%) were male and the median age was 9 years (IQR, 6-11). Of the 196 participants, 87 (44.4%) tested positive for SARS-CoV-2 and 105 (53.6%) tested negative by both self- and health care worker-collected swabs. Two children tested positive by self- or health care worker-collected swab alone; 1 child had an invalid health care worker swab. Compared with health care worker-collected swabs, self-collected swabs had 97.8% (95% CI, 94.7%-100.0%) and 98.1% (95% CI, 95.6%-100.0%) positive and negative percent agreement, respectively, and SARS-CoV-2 Ct values did not differ significantly between groups (mean [SD] Ct, self-swab: 26.7 [5.4] vs health care worker swab: 26.3 [6.0]; P = .65).Conclusions and Relevance: After hearing and seeing simple instructional materials, children and adolescents aged 4 to 14 years self-collected nasal swabs that closely agreed on SARS-CoV-2 detection with swabs collected by health care workers. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
30. Association of Secretor Status and Recent Norovirus Infection With Gut Microbiome Diversity Metrics in a Veterans Affairs Population.
- Author
-
Johnson, Jordan A, Read, Timothy D, Petit, Robert A, Marconi, Vincent C, Meagley, Kathryn L, Rodriguez-Barradas, Maria C, Beenhouwer, David O, Brown, Sheldon T, Holodniy, Mark, Lucero-Obusan, Cynthia A, Schirmer, Patricia, Ingersoll, Jessica M, Kraft, Colleen S, Neill, Frederick H, Atmar, Robert L, Kambhampati, Anita K, Cates, Jordan E, Mirza, Sara A, Hall, Aron J, and Cardemil, Cristina V
- Subjects
- *
NOROVIRUS diseases , *GUT microbiome , *VETERANS , *GASTROENTERITIS , *MEDICAL centers - Abstract
Norovirus infection causing acute gastroenteritis could lead to adverse effects on the gut microbiome. We assessed the association of microbiome diversity with norovirus infection and secretor status in patients from Veterans Affairs medical centers. Alpha diversity metrics were lower among patients with acute gastroenteritis but were similar for other comparisons. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Fecal Microbiota Transplant for Clostridium difficile Infection in a Pregnant Patient.
- Author
-
Saeedi, Bejan J., Morison, Doree Gardner, Kraft, Colleen S., and Dhere, Tanvi
- Subjects
- *
FECAL microbiota transplantation , *CLOSTRIDIUM , *CLOSTRIDIOIDES difficile , *PREGNANT women , *FIDAXOMICIN - Abstract
Background: Clostridium difficile infection has been associated with negative outcomes in the general population and in pregnant patients. Fecal microbiota transplant has become the standard for treatment of recurrent as well as refractory C difficile infection.Case: We present a case of a 28-year-old pregnant woman who presented with recurrent C difficile infection despite treatment with vancomycin and fidaxomicin and underwent a successful fecal microbiota transplant through colonoscopy at 18 weeks of gestation. She no longer required antibiotics for the remainder of her pregnancy to treat C difficile and had a term vaginal delivery at 39 weeks of gestation.Conclusion: Our pregnant patient tolerated and responded to a fecal microbiota transplant for treatment of recurrent C difficile infection. Future large-scale studies are needed to determine the efficacy, safety, and long-term effects of manipulating the microbiome in pregnant patients and the neonates. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
32. Genome Sequence-Based Discriminator for Vancomycin-Intermediate Staphylococcus aureus.
- Author
-
Rishishwar, Lavanya, Petit III, Robert A., Kraft, Colleen S., and Jordan, I. King
- Subjects
- *
NUCLEOTIDE sequence , *VANCOMYCIN , *STAPHYLOCOCCUS aureus infections , *GENOMICS , *MACHINE learning , *THERAPEUTICS - Abstract
Vancomycin is the mainstay of treatment for patients with Staphylococcus aureus infections, and reduced susceptibility to vancomycin is becoming increasingly common. Accordingly, the development of rapid and accurate assays for the diagnosis of vancomycin-intermediate S. aureus (VISA) will be critical We developed and applied a genome-based machine-learning approach for discrimination between VISA and vancomycin-susceptible S. aureus (VSSA) using 25 whole-genome sequences. The resulting machine-learning model, based on 14 gene parameters, including 3 molecular typing markers and 11 genes implicated in reduced vancomycin susceptibility, is able to unambiguously distinguish between the VISA and VSSA isolates analyzed here despite the fact that they do not form evolutionarily distinct groups. As such, the model is able to discriminate based on specific genomic markers of antibiotic susceptibility rather than overall sequence relatedness. Subsequent evaluation of the model using leave-one-out validation yielded a classification accuracy of 84%. The machine-learning approach described here provides a generalized framework for the application of genome sequence analysis to the classification of bacteria that differ with respect to clinically relevant phenotypes and should be particularly useful in defining the genomic features that underlie antibiotic resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. SER-109, an Oral Microbiome Therapy for Recurrent Infection.
- Author
-
Feuerstadt, Paul, Louie, Thomas J., Lashner, Bret, Wang, Elaine E. L., Diao, Liyang, Bryant, Jessica A., Sims, Matthew, Kraft, Colleen S., Cohen, Stuart H., Berenson, Charles S., Korman, Louis Y., Ford, Christopher B., Litcofsky, Kevin D., Lombardo, Mary-Jane, Wortman, Jennifer R., Wu, Henry, Auninš, John G., McChalicher, Christopher W. J., Winkler, Jonathan A., and McGovern, Barbara H.
- Abstract
Background: Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria. SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.Methods: We conducted a phase 3, double-blind, randomized, placebo-controlled trial in which patients who had had three or more episodes of C. difficile infection (inclusive of the qualifying acute episode) received SER-109 or placebo (four capsules daily for 3 days) after standard-of-care antibiotic treatment. The primary efficacy objective was to show superiority of SER-109 as compared with placebo in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment. Diagnosis by toxin testing was performed at trial entry, and randomization was stratified according to age and antibiotic agent received. Analyses of safety, microbiome engraftment, and metabolites were also performed.Results: Among the 281 patients screened, 182 were enrolled. The percentage of patients with recurrence of C. difficile infection was 12% in the SER-109 group and 40% in the placebo group (relative risk, 0.32; 95% confidence interval [CI], 0.18 to 0.58; P<0.001 for a relative risk of <1.0; P<0.001 for a relative risk of <0.833). SER-109 led to less frequent recurrence than placebo in analyses stratified according to age stratum (relative risk, 0.24 [95% CI, 0.07 to 0.78] for patients <65 years of age and 0.36 [95% CI, 0.18 to 0.72] for those ≥65 years) and antibiotic received (relative risk, 0.41 [95% CI, 0.22 to 0.79] with vancomycin and 0.09 [95% CI, 0.01 to 0.63] with fidaxomicin). Most adverse events were mild to moderate and were gastrointestinal in nature, with similar numbers in the two groups. SER-109 dose species were detected as early as week 1 and were associated with bile-acid profiles that are known to inhibit C. difficile spore germination.Conclusions: In patients with symptom resolution of C. difficile infection after treatment with standard-of-care antibiotics, oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection. The observed safety profile of SER-109 was similar to that of placebo. (Funded by Seres Therapeutics; ECOSPOR III ClinicalTrials.gov number, NCT03183128.). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Clinical Utilization of DiaSorin Molecular Polymerase Chain Reaction in Pneumocystis Pneumonia.
- Author
-
Damhorst, Gregory L, Broder, Kari J, Overton, Elizabeth C, Rara, Ronelio, Busch, Lindsay M, Burd, Eileen M, Webster, Andrew S, Kraft, Colleen S, and Babiker, Ahmed
- Abstract
Background Pneumocystis jirovecii polymerase chain reaction (PCR) testing is a sensitive diagnostic tool but does not distinguish infection from colonization. Cycle threshold (CT) may correlate with fungal burden and could be considered in clinical decision making. Clinical use of PCR and significance of CT values have not previously been examined with the DiaSorin Molecular platform. Methods Retrospective review of P jirovecii PCR, CT values and clinical data from 18 months in a multihospital academic health system. The diagnostic performance of PCR with respect to pathology and correlation of CT with severity were examined. Results Ninety-nine of 1006 (9.8%) assays from 786 patients in 919 encounters were positive. Among 91 (9.9%) encounters in which P jirovecii pneumonia (PJP) was treated, 41 (45%) were influenced by positive PCR. Negative PCR influenced discontinuation of therapy in 35 cases. Sensitivity and specificity of PCR were 93% (95% CI, 68%–100%) and 94% (95% CI, 91%–96%) with respect to pathology. CT values from deep respiratory specimens were significantly different among treated patients (P = .04) and those with positive pathology results (P <.0001) compared to patients not treated and those with negative pathology, respectively, and was highly predictive of positive pathology results (area under the curve = 0.92). No significant difference was observed in comparisons based on indicators of disease severity. Conclusions Pneumocystis jirovecii PCR was a highly impactful tool in the diagnosis and management of PJP, and use of CT values may have value in the treatment decision process in select cases. Further investigation in a prospective manner is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Condomless receptive anal intercourse is associated with markers of mucosal inflammation in a cohort of men who have sex with men in Atlanta, Georgia.
- Author
-
Kelley, Colleen F., Pollack, Ilana, Yacoub, Rami, Zhu, Zhengyi, Van Doren, Vanessa E., Gumber, Sanjeev, Amara, Rama R., Fedirko, Veronika, Kraft, Colleen S., de Man, Tom J. B., Hu, Yi‐Juan, Grimsley Ackerley, Cassie, Sullivan, Patrick S., and Bostick, Roberd M.
- Subjects
- *
ANAL sex , *MEN who have sex with men , *BIOMARKERS , *INFLAMMATORY mediators , *HIV infection transmission - Abstract
Introduction: We previously showed that the rectal mucosal immune environment among men who have sex with men (MSM) engaging in condomless receptive anal intercourse (CRAI) is immunologically distinct from that of men who do not engage in anal intercourse (AI). Here, we further examined these differences with quantitative immunohistochemistry to better understand the geographic distribution of immune markers of interest. Methods: We enrolled a cohort of MSM engaging in CRAI (n = 41) and men who do not engage in AI (n = 21) between October 2013 and April 2015. Participants were healthy, HIV‐negative men aged 18–45 from the metro Atlanta area. We performed rectal mucosal sampling via rigid sigmoidoscopy during two study visits separated by a median of nine weeks and timed with sexual activity for MSM engaging in CRAI. We used standardized, automated immunohistochemistry and quantitative image analysis to investigate the rectal mucosal distribution of neutrophils (MPO), IL‐17‐producing cells (IL‐17) and Tregs (FOXP3) in the lamina propria, and cellular proliferation (Ki67) and adherens junction protein (E‐cadherin) in the epithelium. We examined associations between biomarker expression and the rectal mucosal microbiota composition by 16s rRNA sequencing. Results: Relative to the colonic crypt base, IL‐17, FOXP3, and MPO expression increased towards the rectal lumen, while Ki67 decreased and E‐cadherin was more uniformly distributed. Throughout the rectal mucosa distribution examined, MSM engaging in CRAI had higher mean lamina propria MPO expression (p = 0.04) and epithelial Ki67 (p = 0.04) compared to controls. There were no significant differences in IL‐17, FOXP3 or E‐cadherin expression. We found no significant associations of the five biomarkers with the global rectal microbiota composition or the individual taxa examined. Conclusions: Understanding the mucosal distribution of inflammatory mediators can enhance our knowledge of the earliest events in HIV transmission. Neutrophil enrichment and crypt epithelial cell proliferation likely represent sub‐clinical inflammation in response to CRAI in the rectal mucosa of MSM, which could increase the risk for HIV acquisition. However, the contributory role of the microbiota in mucosal inflammation among MSM remains unclear. HIV prevention may be enhanced by interventions that reduce inflammation or capitalize on the presence of specific inflammatory mechanisms during HIV exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Diagnosis of Streptococcus pneumoniae infection using circulating antibody secreting cells.
- Author
-
Kyu, Shuya, Ramonell, Richard P., Kuruvilla, Merin, Kraft, Colleen S., Wang, Yun F., Falsey, Ann R., Walsh, Edward E., Daiss, John L., Paulos, Simon, Rajam, Gowrisankar, Wu, Hao, Velusamy, Srinivasan, and Lee, F. Eun-Hyung
- Subjects
- *
ADULTS , *STREPTOCOCCUS pneumoniae , *BACTERIAL diseases , *DIAGNOSIS - Abstract
Background: Streptococcus pneumoniae infections cause morbidity and mortality worldwide. A rapid, simple diagnostic method could reduce the time needed to introduce definitive therapy potentially improving patient outcomes. Methods: We introduce two new methods for diagnosing S. pneumoniae infections by measuring the presence of newly activated, pathogen-specific, circulating Antibody Secreting Cells (ASC). First, ASC were detected by ELISpot assays that measure cells secreting antibodies specific for signature antigens. Second, the antibodies secreted by isolated ASC were collected in vitro in a novel matrix, MENSA (media enriched with newly synthesized antibodies) and antibodies against S. pneumoniae antigens were measured using Luminex immunoassays. Each assay was evaluated using blood from S. pneumoniae and non-S. pneumoniae-infected adult patients. Results: We enrolled 23 patients with culture-confirmed S. pneumoniae infections and 24 controls consisting of 12 non-S. pneumoniae infections, 10 healthy donors and two colonized with S. pneumoniae. By ELISpot assays, twenty-one of 23 infected patients were positive, and all 24 controls were negative. Using MENSA samples, four of five S. pneumoniae-infected patients were positive by Luminex immunoassays while all five non-S. pneumoniae-infected patients were negative. Conclusion: Specific antibodies produced by activated ASC may provide a simple diagnostic for ongoing S. pneumoniae infections. This method has the potential to diagnose acute bacterial infections. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Teaching Laboratory Medicine to Medical Students.
- Author
-
Molinaro, Ross J., Winkler, Anne M., Kraft, Colleen S., Fantz, Corinne R., Stowell, Sean R., Ritchie, James C., Koch, David D., Heron, Sheryl, Liebzeit, Jason, Santen, Sally A., and Guarner, Jeannette
- Subjects
- *
ACHIEVEMENT tests , *CLINICAL pathology , *CURRICULUM , *INTELLECT , *CASE studies , *PROBABILITY theory , *QUESTIONNAIRES , *SATISFACTION , *STUDENTS , *T-test (Statistics) , *CLINICAL competence , *TEACHING methods , *EVALUATION research , *HUMAN services programs , *PRE-tests & post-tests , *EVALUATION of human services programs , *DESCRIPTIVE statistics , *EDUCATION ,STUDY & teaching of medicine - Abstract
Context.--Laboratory medicine is an integral component of patient care. Approximately 60% to 70% of medical decisions are based on laboratory results. Physicians in specialties that order the tests are teaching medical students laboratory medicine and test use with minimal input from laboratory scientists who implement and maintain the quality control for those tests. Objective.--To develop, implement, and evaluate a 1.5- day medical student clinical laboratory experience for fourth-year medical students in their last month of training. Design.--The experience was devised and directed by laboratory scientists and included a panel discussion, laboratory tours, case studies that focused on the goals and objectives recently published by the Academy of Clinical Laboratory Physicians and Scientists, and medical student presentations highlighting salient points of the experience. The same knowledge quiz was administered at the beginning and end of the experience and 84 students took both quizzes. Results.--A score of 7 or more was obtained by 16 students (19%) on the initial quiz, whereas 34 (40%) obtained the same score on the final quiz; the improvement was found to be statistically significant (P = .002; t = 3.215), particularly in 3 out of the 10 questions administered. Conclusions.--Although the assessment can only measure a small amount of knowledge recently acquired, the improvement observed by fourth-year medical students devoting a short period to learning laboratory medicine principles was encouraging. This medical student clinical laboratory experience format allowed teaching of a select group of laboratory medicine principles in 1.5 days to an entire medical school class. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
38. Initial Costs of Ebola Treatment Centers in the United States.
- Author
-
Herstein, Jocelyn J., Biddinger, Paul D., Kraft, Colleen S., Saiman, Lisa, Gibbs, Shawn G., Smith, Philip W., Hewlett, Angela L., and Lowe, John J.
- Subjects
- *
MEDICAL care costs ,TREATMENT of Ebola virus diseases - Abstract
A letter to the editor is presented discussing a study describing the initial preparation costs incurred by designated Ebola treatment centers (ETCs) in the U.S., describing the start-up costs and ongoing maintenance costs of Ebola virus disease (EVD) programs underscoring the need for specialized facilities to treat EVD.
- Published
- 2016
- Full Text
- View/download PDF
39. Bioaerosol Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Referral Center with Critically Ill Coronavirus Disease 2019 (COVID-19) Patients March–May 2020.
- Author
-
Lane, Morgan A, Brownsword, Erik A, Babiker, Ahmed, Ingersoll, Jessica M, Waggoner, Jesse, Ayers, Marie, Klopman, Matthew, Uyeki, Timothy M, Lindsley, William G, and Kraft, Colleen S
- Subjects
- *
CROSS infection prevention , *AEROSOLS , *COVID-19 , *CRITICALLY ill , *VIRAL load , *PATIENTS , *ANALYTICAL biochemistry , *INFECTIOUS disease transmission , *MEDICAL referrals , *COLLECTION & preservation of biological specimens , *PERSONAL protective equipment , *POLYMERASE chain reaction - Abstract
Background Previous research has shown that rooms of patients with coronavirus disease 2019 (COVID-19) present the potential for healthcare-associated transmission through aerosols containing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, data on the presence of these aerosols outside of patient rooms are limited. We investigated whether virus-containing aerosols were present in nursing stations and patient room hallways in a referral center with critically ill COVID-19 patients. Methods Eight National Institute for Occupational Safety and Health BC 251 2-stage cyclone samplers were set up throughout 6 units, including nursing stations and visitor corridors in intensive care units and general medical units, for 6 h each sampling period. Samplers were placed on tripods which held 2 samplers positioned 102 cm and 152 cm above the floor. Units were sampled for 3 days. Extracted samples underwent reverse transcription polymerase chain reaction for selected gene regions of the SARS-CoV-2 virus nucleocapsid and the housekeeping gene human RNase P as an internal control. Results The units sampled varied in the number of laboratory-confirmed COVID-19 patients present on the days of sampling. Some of the units included patient rooms under negative pressure, while most were maintained at a neutral pressure. Of 528 aerosol samples collected, none were positive for SARS-CoV-2 RNA by the estimated limit of detection of 8 viral copies/m3 of air. Conclusions Aerosolized SARS-CoV-2 outside of patient rooms was undetectable. While healthcare personnel should avoid unmasked close contact with each other, these findings may provide reassurance for the use of alternatives to tight-fitting respirators in areas outside of patient rooms during the current pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. An Ounce of Prevention Is Equivalent to How Much Decolonization Exactly?
- Author
-
Woodworth, Michael H, Kwon, Jennie H, and Kraft, Colleen S
- Subjects
- *
HOST-bacteria relationships , *LENGTH of stay in hospitals , *GUT microbiome , *TREATMENT duration , *MULTIDRUG resistance , *FECAL microbiota transplantation ,DISEASE relapse prevention - Published
- 2021
- Full Text
- View/download PDF
41. Retinopathy and Systemic Disease Morbidity in Severe COVID-19.
- Author
-
Shantha, Jessica G., Auld, Sara C, Anthony, Casey, Ward, Laura, Adelman, Max W., Maier, Cheryl L., Price, Kenneth W., Jacob, Jesse T, Fashina, Tolulope, Randleman, Casey, Xu, Lucy T., Barnett, Joshua, Sadan, Ofer, Kandiah, Prem A., Varkey, Jay B., Kraft, Colleen S., Rouphael, Nadine, Linderman, Susanne, Ahmed, Rafi, and Drews-Botsch, Carolyn
- Subjects
- *
COVID-19 , *DIABETIC retinopathy , *RETINAL artery occlusion , *INTENSIVE care units , *TREATMENT effectiveness , *MECHANICAL shock , *COMORBIDITY - Abstract
To assess the prevalence of retinopathy and its association with systemic morbidity and laboratory indices of coagulation and inflammatory dysfunction in severe COVID-19. Retrospective, observational cohort study. Adult patients hospitalized with severe COVID-19 who underwent ophthalmic examination from April to July 2020 were reviewed. Retinopathy was defined as one of the following: 1) Retinal hemorrhage; 2) Cotton wool spots; 3) Retinal vascular occlusion. We analyzed medical comorbidities, sequential organ failure assessment (SOFA) scores, clinical outcomes, and laboratory values for their association with retinopathy. Thirty-seven patients with severe COVID-19 were reviewed, the majority of whom were female (n = 23, 62%), Black (n = 26, 69%), and admitted to the intensive care unit (n = 35, 95%). Fourteen patients had retinopathy (38%) with retinal hemorrhage in 7 (19%), cotton wool spots in 8 (22%), and a branch retinal artery occlusion in 1 (3%) patient. Patients with retinopathy had higher SOFA scores than those without retinopathy (8.0 vs. 5.3, p =.03), higher rates of respiratory failure requiring invasive mechanical ventilation and shock requiring vasopressors (p <.01). Peak D-dimer levels were 28,971 ng/mL in patients with retinopathy compared to 12,575 ng/mL in those without retinopathy (p =.03). Peak CRP was higher in patients with cotton wool spots versus those without cotton wool spots (354 mg/dL vs. 268 mg/dL, p =.03). Multivariate logistic regression modeling showed an increased risk of retinopathy with higher peak D-dimers (aOR 1.32, 95% CI 1.01–1.73, p =.04) and male sex (aOR 9.6, 95% CI 1.2–75.5, p =.04). Retinopathy in severe COVID-19 was associated with greater systemic disease morbidity involving multiple organs. Given its association with coagulopathy and inflammation, retinopathy may offer insight into disease pathogenesis in patients with severe COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Current Capabilities of Gut Microbiome-Based Diagnostics and the Promise of Clinical Application.
- Author
-
Damhorst, Gregory L, Adelman, Max W, Woodworth, Michael H, and Kraft, Colleen S
- Subjects
- *
GUT microbiome , *HUMAN microbiota , *CELL culture , *MEASURING instruments - Abstract
There is increasing evidence for the importance of the gut microbiome in human health and disease. Traditional and modern technologies - from cell culture to next generation sequencing - have facilitated these advances in knowledge. Each of the tools employed in measuring the microbiome exhibits unique capabilities that may be leveraged for clinical diagnostics. However, much still needs to be done to standardize the language and metrics by which a microbiome is characterized. Here we review the capabilities of gut microbiome-based diagnostics, review selected examples, and discuss the outlook towards clinical application. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. The Effect of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mitigation Strategies on Seasonal Respiratory Viruses: A Tale of 2 Large Metropolitan Centers in the United States.
- Author
-
Sherman, Amy C, Babiker, Ahmed, Sieben, Andrew J, Pyden, Alexander, Steinberg, James, Kraft, Colleen S, Koelle, Katia, and Kanjilal, Sanjat
- Subjects
- *
PREVENTION of infectious disease transmission , *RESPIRATORY syncytial virus , *COVID-19 , *ACADEMIC medical centers , *INFLUENZA A virus , *VIRAL load , *PUBLIC health , *COMPARATIVE studies , *SEASONAL influenza , *INFLUENZA B virus , *RESPIRATORY syncytial virus infections , *COVID-19 pandemic , *INFECTIOUS disease transmission - Abstract
To assess the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on seasonal respiratory viruses, absolute case counts and viral reproductive rates from 2019–2020 were compared against previous seasons. Our findings suggest that the public health measures implemented to reduce SARS-CoV-2 transmission significantly reduced the transmission of other respiratory viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021.
- Author
-
Malenfant, Jason H., Joyce, Allison, Choi, Mary J., Cossaboom, Caitlin M., l, Amy N., Harcourt, Brian H., Atmar, Robert L., Villanueva, Julie M., Bell, Beth P., Hahn, Christine, Loehr, Jamie, Davey, Richard T., Sprecher, Armand, Kraft, Colleen S., Shoemaker, Trevor, Montgomery, Joel M., Helfand, Rita, Damon, Inger K., Frey, Sharon E., and Chen, Wilbur H.
- Subjects
- *
VACCINATION , *IMMUNIZATION , *VIRAL vaccines , *ATTITUDE (Psychology) , *EBOLA virus , *SURVEYS , *HEALTH literacy , *VACCINE effectiveness , *DESCRIPTIVE statistics - Abstract
On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Critical Care Management of the Patient with Clostridioides difficile.
- Author
-
Adelman, Max W., Woodworth, Michael H., Shaffer, Virginia O., Martin, Greg S., and Kraft, Colleen S.
- Subjects
- *
DISEASE risk factors , *INFLAMMATORY bowel diseases , *PATIENT care , *INFECTION prevention , *CRITICAL care medicine - Abstract
Objectives: To review published clinical evidence on management of Clostridioides difficile infection in critically ill patients.Data Sources: We obtained relevant studies from a PubMed literature review and bibliographies of reviewed articles.Study Selection: We selected English-language studies addressing aspects of C. difficile infection relevant to critical care clinicians including epidemiology, risk factors, diagnosis, treatment, and prevention, with a focus on high-quality clinical evidence.Data Extraction: We reviewed potentially relevant studies and abstracted information on study design, methods, patient selection, and results of relevant studies. This is a synthetic (i.e., not systematic) review.Data Synthesis: C. difficile infection is the most common healthcare-associated infection in the United States. Antibiotics are the most significant C. difficile infection risk factor, and among antibiotics, cephalosporins, clindamycin, carbapenems, fluoroquinolones, and piperacillin-tazobactam confer the highest risk. Age, diabetes mellitus, inflammatory bowel disease, and end-stage renal disease are risk factors for C. difficile infection development and mortality. C. difficile infection diagnosis is based on testing appropriately selected patients with diarrhea or on clinical suspicion for patients with ileus. Patients with fulminant disease (C. difficile infection with hypotension, shock, ileus, or megacolon) should be treated with oral vancomycin and IV metronidazole, as well as rectal vancomycin in case of ileus. Patients who do not respond to initial therapy should be considered for fecal microbiota transplant or surgery. Proper infection prevention practices decrease C. difficile infection risk.Conclusions: Strong clinical evidence supports limiting antibiotics when possible to decrease C. difficile infection risk. For patients with fulminant C. difficile infection, oral vancomycin reduces mortality, and adjunctive therapies (including IV metronidazole) and interventions (including fecal microbiota transplant) may benefit select patients. Several important questions remain regarding fulminant C. difficile infection management, including which patients benefit from fecal microbiota transplant or surgery. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
46. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.
- Author
-
Dean, Christina L., Hooper, Jay W., Dye, John M., Zak, Samantha E., Koepsell, Scott A., Corash, Laurence, Benjamin, Richard J., Kwilas, Steve, Bonds, Shannon, Winkler, Anne M., and Kraft, Colleen S.
- Subjects
- *
EBOLA virus disease , *IMMUNE response , *RECOMBINANT antibodies , *EBOLA virus , *NEUTRALIZATION tests , *CONVALESCENT plasma , *THERAPEUTIC use of immunoglobulins , *EBOLA virus disease prevention , *IMMUNOGLOBULIN analysis , *RESEARCH , *IMMUNOGLOBULINS , *IMMUNIZATION , *BLOOD plasma , *HETEROCYCLIC compounds , *ANIMAL experimentation , *VIRAL load , *CONVALESCENCE , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *IMMUNITY , *RESEARCH funding , *VIRAL antibodies - Abstract
Background: In 2014, passive immunization by transfusion of Ebola convalescent plasma (ECP) was considered for treating patients with acute Ebola virus disease (EVD). Early Ebola virus (EBOV) seroconversion confers a survival advantage in natural infection, hence transfusion of ECP plasma with high levels of neutralizing EBOV antibodies is a potential passive immune therapy. Techniques to reduce the risk of other transfusion-transmitted infections (TTIs) are warranted as recent ECP survivors are ineligible as routine blood donors. As part of an ongoing clinical trial to evaluate the safety and effectiveness of ECP, the impact of amotosalen/UVA pathogen reduction technology (PRT) on EBOV antibody characteristics was examined.Study Design and Methods: Serum and plasma samples were collected from EVD-recovered subjects at multiple timepoints and evaluated by ELISA for antibodies to recombinant EBOV glycoprotein (GP) and irradiated whole EBOV antigen, as well as for EBOV microneutralization, classic plaque reduction neutralization test (PRNT) and EBOV pseudovirion neutralization assay (PsVNA) activity.Results: Six subjects donated 40 individual ECP units. Substantial antibody titers and neutralizing activity results were demonstrated but were generally lower for the ACD plasma samples compared to the serum samples. Anti-EBOV titers by all assays remained essentially unchanged after PRT.Conclusion: Treatment of ECP with PRT to reduce the risk of TTI did not significantly reduce EBOV IgG antibody titers or neutralizing activity. Although ECP was used in the treatment of repatriated patients, no PRT units from this study were transfused to EVD patients. This inventory of PRT-treated ECP is currently available for future clinical evaluation. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
47. Design Strategies for Biocontainment Units to Reduce Risk During Doffing of High-level Personal Protective Equipment.
- Author
-
Wong, Maria F, Matić, Zorana, Campiglia, Gabrielle C, Zimring, Craig M, Mumma, Joel M, Kraft, Colleen S, Casanova, Lisa M, Durso, Francis T, Walsh, Victoria L, Shah, Puja Y, Shane, Andi L, Jacob, Jesse T, and Dubose, Jennifer R
- Subjects
- *
PREVENTION of psychological stress , *PREVENTION of communicable diseases , *POSTURAL balance , *HOSPITAL building design & construction , *INDUSTRIAL safety , *PERSONAL protective equipment , *RISK-taking behavior , *SHOES , *PHYSIOLOGICAL stress , *WORK design , *JOB performance - Abstract
Background Few data exist to guide the physical design of biocontainment units, particularly the doffing area. This can impact the contamination risk of healthcare workers (HCWs) during doffing of personal protective equipment (PPE). Methods In phase I of our study, we analyzed simulations of a standard patient care task with 56 trained HCWs focusing on doffing of high-level PPE. In phase II, using a rapid cycle improvement approach, we tested different balance aids and redesigned doffing area layouts with 38 students. In phase III, we tested 1 redesigned layout with an additional 10 trained HCWs. We assessed the effectiveness of design changes on improving the HCW performance (measured by occurrence and number of risky behaviors) and reducing the physical and cognitive load by comparing the results from phase I and phase III. Results The physical load was highest when participants were removing their shoe covers without any balance aid; the use of a chair required the lowest physical effort, followed by horizontal and vertical grab bars. In the revised design (phase III), the overall performance of participants improved. There was a significant decrease in the number of HCW risky behaviors (P =.004); 5 risky behaviors were eliminated and 2 others increased. There was a significant decrease in physical load when removing disposable shoe covers (P =.04), and participants reported a similar workload in the redesigned doffing layout (P =.43). Conclusions Through optimizing the design and layout of the doffing space, we reduced risky behaviors of HCWs during doffing of high-level PPE. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
48. Common Behaviors and Faults When Doffing Personal Protective Equipment for Patients With Serious Communicable Diseases.
- Author
-
Mumma, Joel M, Durso, Francis T, Casanova, Lisa M, Erukunuakpor, Kimberly, Kraft, Colleen S, Ray, Susan M, Shane, Andi L, Walsh, Victoria L, Shah, Puja Y, Zimring, Craig, DuBose, Jennifer, and Jacob, Jesse T
- Subjects
- *
ATTITUDE (Psychology) , *COMMUNICABLE diseases , *PREVENTION of communicable diseases , *EBOLA virus disease , *GLOVES , *HAND washing , *INDUSTRIAL hygiene , *INDUSTRIAL safety , *PROTECTIVE clothing , *PERSONAL protective equipment , *RISK perception , *EMPLOYEES' workload - Abstract
Background The safe removal of personal protective equipment (PPE) can limit transmission of serious communicable diseases, but this process poses challenges to healthcare workers (HCWs). Methods We observed 41 HCWs across 4 Ebola treatment centers in Georgia doffing PPE for simulated patients with serious communicable diseases. Using human factors methodologies, we obtained the details, sequences, and durations of doffing steps; identified the ways each step can fail (failure modes [FMs]); quantified the riskiness of FMs; and characterized the workload of doffing steps. Results Eight doffing steps were common to all hospitals—removal of boot covers, gloves (outer and inner pairs), the outermost garment, the powered air purifying respirator (PAPR) hood, and the PAPR helmet assembly; repeated hand hygiene (eg, with hand sanitizer); and a final handwashing with soap and water. Across hospitals, we identified 256 FMs during the common doffing steps, 61 of which comprised 19 common FMs. Most of these common FMs were above average in their riskiness at each hospital. At all hospitals, hand hygiene, removal of the outermost garment, and removal of boot covers were above average in their overall riskiness. Measurements of workload revealed that doffing steps were often mentally demanding, and this facet of workload correlated most strongly with the effortfulness of a doffing step. Conclusions We systematically identified common points of concern in protocols for doffing high-level PPE. Addressing FMs related to hand hygiene and the removal of the outermost garment, boot covers, and PAPR hood could improve HCW safety when doffing high-level PPE. We identified ways that doffing protocols for high-level personal protective equipment may fail to protect healthcare workers. Hand hygiene, removing the outermost garment, boot covers, and respirator hood harbored the greatest risk and failed in similar ways across different hospitals. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
49. Developing and Assessing the Feasibility of a Home-based Preexposure Prophylaxis Monitoring and Support Program.
- Author
-
Siegler, Aaron J, Mayer, Kenneth H, Liu, Albert Y, Patel, Rupa R, Ahlschlager, Lauren M, Kraft, Colleen S, Fish, Rossi, Wiatrek, Sarah E, and Sullivan, Patrick S
- Subjects
- *
HIV prevention , *PSYCHOLOGY of HIV-positive persons , *MEDICAL care , *PREVENTIVE medicine , *PATIENTS , *HOME environment , *HUMAN services programs , *EVALUATION of human services programs - Abstract
We piloted PrEP@Home, a preexposure prophylaxis system of remote laboratory and behavioral monitoring designed to replace routine quarterly follow-up visits with home care to reduce the patient and provider burden. The system was highly acceptable and in-demand for future use, and more than one-third of participants reported greater likelihood of persisting in care if available. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1.
- Author
-
McElroy, Anita K., Shrivastava-Ranjan, Punya, Harmon, Jessica R., Martines, Roosecelis B., Silva-Flannery, Luciana, Flietstra, Timothy D., Kraft, Colleen S., Mehta, Aneesh K., Lyon, G. Marshall, Varkey, Jay B., Ribner, Bruce S., Nichol, Stuart T., Zaki, Sherif R., and Spiropoulou, Christina F.
- Subjects
- *
MACROPHAGE activation syndrome , *EBOLA virus disease , *MACROPHAGE activation , *RESEARCH funding - Abstract
Ebola virus disease (EVD) is associated with elevated cytokine levels, and hypercytokinemia is more pronounced in fatal cases. This type of hyperinflammatory state is reminiscent of 2 rheumatologic disorders known as macrophage activation syndrome and hemophagocytic lymphohistiocytosis, which are characterized by macrophage and T-cell activation. An evaluation of 2 cohorts of patients with EVD revealed that a marker of macrophage activation (sCD163) but not T-cell activation (sCD25) was associated with severe and fatal EVD. Furthermore, substantial immunoreactivity of host tissues to a CD163-specific antibody, predominantly in areas of extensive immunostaining for Ebola virus antigens, was observed in fatal cases. These data suggest that host macrophage activation contributes to EVD pathogenesis and that directed antiinflammatory therapies could be beneficial in the treatment of EVD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.